Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Imatinib

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    255 result(s) found for: Imatinib. Displaying page 9 of 13.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next»
    EudraCT Number: 2006-007091-15 Sponsor Protocol Number: CSTI571ENL18 Start Date*: 2007-09-03
    Sponsor Name:ErasmusMC
    Full Title: Glivec (imatinib mesylate) in systemic sclerosis, a pilot study
    Medical condition: systemic sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039710 Scleroderma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001303-19 Sponsor Protocol Number: A6181047 Start Date*: 2005-10-18
    Sponsor Name:PFIZER
    Full Title: A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 ADMINISTERED IN A CONTINUOUS DAILY REGIMEN IN PATIENTS WITH ADVANCED GASTRO INTESTINAL STROMAL TUMOR
    Medical condition: Imatinib mesylate-resistant malignant gastrointestinal stromal tumor
    Disease: Version SOC Term Classification Code Term Level
    6.1 10053548 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-002538-20 Sponsor Protocol Number: EORTC 62027 Start Date*: 2006-02-24
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Phase 2 study of Glivec (Imatinib) in locally advanced and/or metastatic soft tissue sarcomas expressing the t(17;22)(q22;q13) translocation resulting in a COL1A1/PDGF rearrangement i.e. DermatoFib...
    Medical condition: Soft tissue sarcomas are a family of malignant diseases originating from mesenchymal cells. Two types of theses sarcomas, dermatofibrosarcoma protuberans (DFSP) and giant cell fibriblastoma(GCF), a...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10057070 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-002280-24 Sponsor Protocol Number: NILG-HES 1-03 Start Date*: 2004-07-26
    Sponsor Name:AZIENDA OSPEDALIERA "OSPEDALI RIUNITI DI BERGAMO" (A.O. DI RILIEVO NAZIONALE)
    Full Title: THERAPEUTIC AND BIOLOGICAL EFFECTS OF IMATINIB MESYLATE (STI571) IN PRIMARY HYPERESINOPHILIC SYNDROME (HES), CHRONIC EOSINOPHILIC LEUKEMIA (CEL) AND CHRONIC IDIOPHATIC HYPEREOSINOPHILIA (CIH): A ST...
    Medical condition: HYPEREOSINOPHILIC SYNDROME (HES, CEL, CIH)
    Disease: Version SOC Term Classification Code Term Level
    6.1 10024324 HLGT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001614-41 Sponsor Protocol Number: CSTI571BIT06 Start Date*: 2005-05-19
    Sponsor Name:NOVARTIS FARMA
    Full Title: OPEN-LABEL TRIAL OF GLIVEC IMATINIB MESYLATE IN PATIENTS WITH REFRACTORY DESMOPLASTIC SMALL ROUND CELL TUMORS DSRCT EXPRESSING A MOLECULAR TARGET OF GLIVEC PDGF-R AND/OR C-KIT
    Medical condition: TREATMENT OF PATIENTS WITH REFRACTORY DESMOPLASTIC SMALL ROUND CELL TUMORS DSRCT .
    Disease: Version SOC Term Classification Code Term Level
    6.1 10039491 PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-001537-15 Sponsor Protocol Number: CSTI571BDE28 Start Date*: 2006-03-14
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Open-label trial of imatinib mesylate (Glivec, formerly known as STI571) in combination with vinorelbine (Navelbine) for patients with advanced breast carcinoma
    Medical condition: carcinoma breast
    Disease: Version SOC Term Classification Code Term Level
    M15 10007305 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001508-19 Sponsor Protocol Number: IMA-GVH Start Date*: 2007-09-06
    Sponsor Name:AZIENDA OSPEDALIERA S. CARLO
    Full Title: TRATTAMENTO CON IMATINIB MESILATO DELLA GVH CRONICA SEVERA SCLERODERMA-LIKE REFRATTARIA ALLA TERAPIA IMMUNOSOPRESSIVA CONVENZIONALE
    Medical condition: GVH CRONICA ESTESA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018651 Graft versus host disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000657-29 Sponsor Protocol Number: CSTI571K2301 Start Date*: 2005-07-12
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized open-label study of 400 mg versus 800 mg of Gleevec/Glivec (imatinib mesylate) in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP)...
    Medical condition: Newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP)
    Disease: Version SOC Term Classification Code Term Level
    M15 10009013
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) ES (Completed) IT (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000218-19 Sponsor Protocol Number: CSTI571BDE59 Start Date*: 2008-05-21
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A single stage phase II, multi-centre, open label study of Glivec in combination with pioglitazone, etoricoxib, dexamethasone and low-dose treosulfane for anti-inflammatory and angiostatic treatmen...
    Medical condition: prostrate carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036921 Prostate carcinoma LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-006185-15 Sponsor Protocol Number: SPIRIT 2 Start Date*: 2008-04-22
    Sponsor Name:Newcastle-upon-Tyne Hospitals NHS Trust
    Full Title: STI571 Prospective International RandomIsed Trial 2 - A phase III, prospective randomised comparison of imatinib (STI571, Glivec/Gleevec) 400mg daily versus dasatinib (Sprycel) 100mg daily in pati...
    Medical condition: newly-diagnosed chronic-phase Chronic myeloid leukaemia (CML)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009013 Chronic myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-002544-27 Sponsor Protocol Number: CSTI571BDE78T Start Date*: 2011-10-18
    Sponsor Name:Technische Universitaet Muenchen Fakultaet fuer Medizin
    Full Title: Prospective, explorative trial for the detection of circulating cell-free tumor DNA in the plasma of patients with gastrointestinal stromal tumors (GIST) harboring activating mutations of CKIT or P...
    Medical condition: Patients with gastrointestinal stromal tumor (GIST) harboring activating mutations of CKIT or PDGFRA pre/post surgery or pre/under treatment with a Tyrokinase Inhibitors or progressive disease irre...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003581-34 Sponsor Protocol Number: DASATINIB compassionate use Start Date*: 2006-07-27
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: DASATINIB compassionate use
    Medical condition: CML and Ph
    Disease: Version SOC Term Classification Code Term Level
    6.1 10000880 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001603-42 Sponsor Protocol Number: AIL0115 Start Date*: 2015-09-22
    Sponsor Name:AIL CATANIA ASSOCIAZIONE ITALIANA CONTRO LEUCEMIE-LINFOMI E MIELOMA ONLUS
    Full Title: “Arrest Imatinib or Dasatinib in CML patients with Deep Molecular Responses” (AID MORE)
    Medical condition: Chronic phase CML patients with BCR-ABL/ABLIS transcript levels below MR3 (<0.1%) and above MR4.5 (>0.0032%) at the time of accrual.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10009015 Chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004162-34 Sponsor Protocol Number: AB12004 Start Date*: 2015-01-02
    Sponsor Name:AB Science
    Full Title: A prospective, multicenter, randomized, double-blind, placebo-controlled, two-parallel groups, phase III clinical trial to compare the efficacy and safety of masitinib to placebo in patients with l...
    Medical condition: stromal gastrointestinal cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) CZ (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020305-32 Sponsor Protocol Number: CRAD001CIT27T Start Date*: 2010-08-06
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: A phase II, open label study to evaluate the activity and safety of Everolimus in association to Imatinib in PDGFRA-D842V unresectable or metastatic gastrointestinal stromal tumours (GISTs)as...
    Medical condition: patients with unresectable and/or metastatic gastrointestinal stromal tumours with exon 18 PDGFRA mutation
    Disease: Version SOC Term Classification Code Term Level
    12.1 10051066 Gastrointestinal stromal tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-003502-16 Sponsor Protocol Number: DasaHIT Start Date*: 2016-08-11
    Sponsor Name:Friedrich-Schiller-Universität Jena
    Full Title: Treatment optimization for patients with chronic myeloid leukemia (CML) with treatment naïve disease (1st line) and patients with resistance or intolerance against alternative Abl-Kinase Inhibitors...
    Medical condition: Chronic Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10009700 CML LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004950-25 Sponsor Protocol Number: D-00272-CT2014001 Start Date*: 2008-01-06
    Sponsor Name:Cell Medica Ltd
    Full Title: WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study
    Medical condition: Acute Myeloid Leukaemia and Chronic Myeloid Leukaemia in adults.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009013 Chronic myeloid leukaemia PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001334-18 Sponsor Protocol Number: CarPAs Start Date*: 2020-09-10
    Sponsor Name:Associazione Italiana Pazienti Leucemia Mieloide Cronica (AIPLMC)
    Full Title: Cardiovascular assessment of Ponatinib as treatment option in chronic phase chronic myeloid leukemia after failure of Imatinib and Bosutinib (CarPAs)
    Medical condition: Chronic Myeloid Leukemia (CML) in Chronic Phase (CP)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009013 Chronic myeloid leukaemia PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009013 Chronic myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-005248-33 Sponsor Protocol Number: CML1415 Start Date*: 2018-06-21
    Sponsor Name:Fondazione GIMEMA Franco Mandelli ONLUS
    Full Title: SUSTRENIM Study – GIMEMA CML1415 Sustained treatment-free remission in BCR-ABL+ chronic myeloid leukemia: a prospective study comparing Nilotinib versus Imatinib with switch to Nilotinib in absence...
    Medical condition: Chronic myeloid leukemia (CML) in chronic phase (CP)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10009015 Chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) BE (Completed) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004998-33 Sponsor Protocol Number: CAMN107ADE22T Start Date*: 2016-06-24
    Sponsor Name:University of Heidelberg
    Full Title: Multicenter prospective trial after first or second unsuccessful treatment discontinuation in chronic myeloid leukemia estimating the efficacy of nilotinib in inducing the persistence of molecular ...
    Medical condition: CML-Patients in chronic phase having failed a prior attempt to stop imatinib or other TKIs therapy either within EURO-SKI or not and are pretreated at least one year with any TKI after 1st stop
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) NL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 30 07:15:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA